Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
215.6 USD | -0.33% | -2.32% | -16.67% |
Mar. 25 | Dyne Therapeutics President, CEO Joshua Brumm Resigns, John Cox Named Successor; Shares Drop 7% Pre-Bell | MT |
Mar. 19 | BIOGEN : Jefferies confirms its Buy rating on the stock | CF |
Evolution of the average Target Price on Biogen Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Biogen Inc.
Canaccord Genuity | |
UBS | |
Oppenheimer | |
Needham & Co. | |
Wells Fargo Securities | |
RBC Capital Markets | |
Baird | |
Scotiabank | |
Stifel Nicolaus | |
TD Cowen | |
Piper Sandler | |
Wedbush | |
BofA Securities | |
Morgan Stanley | |
Raymond James | |
HSBC | |
Mizuho Securities | |
BMO Capital | |
Barclays | |
Atlantic Equities | |
Goldman Sachs | |
Guggenheim | |
Argus | |
Jefferies & Co. | |
Truist Securities | |
HC Wainwright | |
SVB Securities LLC | |
Cowen | |
JPMorgan Chase | |
SVB Leerink | |
Cantor Fitzgerald | |
Bernstein | |
William Blair & Co. | |
Citigroup | |
Credit Suisse | |
DZ Bank |
EPS Revisions
- Stock
- Equities
- Stock Biogen Inc. - Nasdaq
- Consensus Biogen Inc.